190 related articles for article (PubMed ID: 21684850)
1. Compatibility studies of nateglinide with excipients in immediate release tablets.
Pani NR; Nath LK; Acharya S
Acta Pharm; 2011 Jun; 61(2):237-47. PubMed ID: 21684850
[TBL] [Abstract][Full Text] [Related]
2. Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing.
Verma RK; Garg S
J Pharm Biomed Anal; 2005 Jul; 38(4):633-44. PubMed ID: 15967291
[TBL] [Abstract][Full Text] [Related]
3. Compatibility studies of promethazine hydrochloride with tablet excipients by means of thermal and non-thermal methods.
Thumma S; Repka MA
Pharmazie; 2009 Mar; 64(3):183-9. PubMed ID: 19348341
[TBL] [Abstract][Full Text] [Related]
4. Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
Wairkar S; Gaud R; Jadhav N
J Pharm Pharmacol; 2017 Sep; 69(9):1099-1109. PubMed ID: 28590055
[TBL] [Abstract][Full Text] [Related]
5. IDENTIFICATION OF PHARMACEUTICAL EXCIPIENT BEHAVIOR OF CHICKPEA (CICER ARIETINUM) STARCH IN GLICLAZIDE IMMEDIATE RELEASE TABLETS.
Meka VS; Yee P; Sheshala R
Acta Pol Pharm; 2016; 73(2):469-78. PubMed ID: 27180440
[TBL] [Abstract][Full Text] [Related]
6. Effect of two hydrophobic polymers on the release of gliclazide from their matrix tablets.
Hussain T; Saeed T; Mumtaz AM; Javaid Z; Abbas K; Awais A; Idrees HA
Acta Pol Pharm; 2013; 70(4):749-57. PubMed ID: 23923399
[TBL] [Abstract][Full Text] [Related]
7. Development of controlled release tablet by optimizing HPMC: consideration of theoretical release and RSM.
Pani NR; Nath LK
Carbohydr Polym; 2014 Apr; 104():238-45. PubMed ID: 24607183
[TBL] [Abstract][Full Text] [Related]
8. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations.
Verma RK; Garg S
J Pharm Biomed Anal; 2004 May; 35(3):449-58. PubMed ID: 15137971
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of drug-excipient interaction in the formulation of celecoxib tablets.
Bozdağ-Pehlivan S; Subaşi B; Vural I; Unlü N; Capan Y
Acta Pol Pharm; 2011; 68(3):423-33. PubMed ID: 21648198
[TBL] [Abstract][Full Text] [Related]
10. Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.
Bashir S; Nazir I; Khan H; Alamgeer ; Asad M; ul Hassnain F; Qamar S
Pak J Pharm Sci; 2013 Nov; 26(6):1229-35. PubMed ID: 24191331
[TBL] [Abstract][Full Text] [Related]
11. Determination of the nateglinide polymorphic purity through DSC.
Bruni G; Berbenni V; Milanese C; Girella A; Cardini A; Lanfranconi S; Marini A
J Pharm Biomed Anal; 2011 Apr; 54(5):1196-9. PubMed ID: 21216126
[TBL] [Abstract][Full Text] [Related]
12. I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.
Maggi L; Bruni G; Maietta M; Canobbio A; Cardini A; Conte U
Int J Pharm; 2013 Sep; 454(1):562-7. PubMed ID: 23867985
[TBL] [Abstract][Full Text] [Related]
13. II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: co-milling.
Maggi L; Bruni G; Maietta M; Canobbio A; Cardini A; Conte U
Int J Pharm; 2013 Sep; 454(1):568-72. PubMed ID: 23872227
[TBL] [Abstract][Full Text] [Related]
14. Solid-state interaction of stearic acid with povidone and its effect on dissolution stability of capsules.
Desai D; Kothari S; Huang M
Int J Pharm; 2008 Apr; 354(1-2):77-81. PubMed ID: 18194844
[TBL] [Abstract][Full Text] [Related]
15. Compatibility study between ketoprofen and pharmaceutical excipients used in solid dosage forms.
Tiţa B; Fuliaş A; Bandur G; Marian E; Tiţa D
J Pharm Biomed Anal; 2011 Sep; 56(2):221-7. PubMed ID: 21665404
[TBL] [Abstract][Full Text] [Related]
16. Thermal and non-thermal methods to evaluate compatibility of granisetron hydrochloride with tablet excipients.
Late SG; Banga AK
Pharmazie; 2008 Jun; 63(6):453-8. PubMed ID: 18604989
[TBL] [Abstract][Full Text] [Related]
17. A new crystal form of nateglinide.
Li G; Su GQ; Xu QW; Zhu CQ
Yao Xue Xue Bao; 2001 Jul; 36(7):532-4. PubMed ID: 12585087
[TBL] [Abstract][Full Text] [Related]
18. Formulation and evaluation of floating tablet of H2-receptor antagonist.
Kesarla RS; Vora PA; Sridhar BK; Patel G; Omri A
Drug Dev Ind Pharm; 2015; 41(9):1499-511. PubMed ID: 25243639
[TBL] [Abstract][Full Text] [Related]
19. Compatibility studies between carbamazepine and tablet excipients using thermal and non-thermal methods.
Joshi BV; Patil VB; Pokharkar VB
Drug Dev Ind Pharm; 2002 Jul; 28(6):687-94. PubMed ID: 12149961
[TBL] [Abstract][Full Text] [Related]
20. Elimination of metformin-croscarmellose sodium interaction by competition.
Huang WX; Desai M; Tang Q; Yang R; Vivilecchia RV; Joshi Y
Int J Pharm; 2006 Mar; 311(1-2):33-9. PubMed ID: 16426778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
